Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

ATRA

Get informed when a big investor buys or sells

+ Follow
Market Cap$87.31M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Atara Biotherapeutics IncAtara Biotherapeutics Inc-8.2-45%--0.3
$-2.33

Current Fair Value

124% downside

Overvalued by 124% based on the discounted cash flow analysis.

Share Statistics

Market cap$87.31 Million
Enterprise Value$94.74 Million
Dividend Yield$- (-)
Earnings per Share$2.61
Beta0.09
Outstanding Shares15,033,000

Return

Return on Equity45.11%ROE
Return on Assets-79.38%
Return on Invested Capital-107.89%

Valuation & Multiples

P/E Ratio-8.21P/E Ratio
PEG2.71PEG
Price to Sales-Price to Sales
Price to Book Ratio-3.23Price to Book Ratio
Enterprise Value to Revenue34.56
Enterprise Value to EBIT-6.19
Enterprise Value to Net Income-6
Total Debt to Enterprise0.11
Debt to Equity-0.29Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.32
Average shareholder expectation
Revenue Estimate
$550,000
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$-0.28
Average shareholder expectation
Revenue Estimate
$750,000
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls2000%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %29.72%▲ 11.51%
Total Invested$51.29M▲ 322.98%
Investors Holding36▲ 2.00%

ESG Score

No data

About Atara Biotherapeutics Inc

CEO: Pascal Touchon